|
Shanghai Henlius Biotech, Inc. (2696.HK) Valoración de DCF
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Shanghai Henlius Biotech, Inc. (2696.HK) Bundle
¡Optimice su tiempo y mejore la precisión con nuestra calculadora DCF (2696HK)! Utilizando datos auténticos de Shanghai Henlius Biotech, Inc. y suposiciones personalizables, esta herramienta le permite pronosticar, analizar y valor (2696HK) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 97.1 | 627.4 | 1,796.5 | 3,432.5 | 5,760.4 | 10,928.8 | 20,734.4 | 39,337.8 | 74,632.7 | 141,595.0 |
| Revenue Growth, % | 0 | 546.2 | 186.34 | 91.07 | 67.82 | 89.72 | 89.72 | 89.72 | 89.72 | 89.72 |
| EBITDA | -794.4 | -869.2 | -717.3 | -331.7 | 973.1 | -5,086.2 | -9,649.6 | -18,307.5 | -34,733.4 | -65,897.1 |
| EBITDA, % | -818.23 | -138.54 | -39.93 | -9.66 | 16.89 | -46.54 | -46.54 | -46.54 | -46.54 | -46.54 |
| Depreciation | 88.1 | 145.0 | 213.7 | 296.4 | 298.6 | 3,050.3 | 5,787.1 | 10,979.4 | 20,830.4 | 39,520.0 |
| Depreciation, % | 90.73 | 23.11 | 11.9 | 8.64 | 5.18 | 27.91 | 27.91 | 27.91 | 27.91 | 27.91 |
| EBIT | -882.5 | -1,014.2 | -931.0 | -628.1 | 674.5 | -5,648.3 | -10,716.0 | -20,330.7 | -38,572.0 | -73,179.7 |
| EBIT, % | -908.95 | -161.65 | -51.82 | -18.3 | 11.71 | -51.68 | -51.68 | -51.68 | -51.68 | -51.68 |
| Total Cash | 2,457.0 | 1,189.8 | 165.5 | 890.1 | 1,077.7 | 5,548.6 | 10,527.0 | 19,972.1 | 37,891.6 | 71,888.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 31.9 | 209.5 | 315.8 | 486.4 | 709.5 | 2,410.1 | 4,572.5 | 8,675.0 | 16,458.4 | 31,225.3 |
| Account Receivables, % | 32.81 | 33.39 | 17.58 | 14.17 | 12.32 | 22.05 | 22.05 | 22.05 | 22.05 | 22.05 |
| Inventories | 138.7 | 325.9 | 448.6 | 808.6 | 808.7 | 4,688.7 | 8,895.5 | 16,876.8 | 32,019.1 | 60,747.5 |
| Inventories, % | 142.83 | 51.95 | 24.97 | 23.56 | 14.04 | 42.9 | 42.9 | 42.9 | 42.9 | 42.9 |
| Accounts Payable | 256.4 | 319.2 | 409.4 | 761.9 | 581.7 | 4,501.9 | 8,541.1 | 16,204.4 | 30,743.5 | 58,327.3 |
| Accounts Payable, % | 264.12 | 50.88 | 22.79 | 22.2 | 10.1 | 41.19 | 41.19 | 41.19 | 41.19 | 41.19 |
| Capital Expenditure | -1,209.7 | -1,615.0 | -1,207.8 | -1,457.8 | -1,080.0 | -7,179.2 | -13,620.5 | -25,841.2 | -49,026.5 | -93,014.3 |
| Capital Expenditure, % | -1245.94 | -257.41 | -67.23 | -42.47 | -18.75 | -65.69 | -65.69 | -65.69 | -65.69 | -65.69 |
| Tax Rate, % | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 | 4.14 |
| EBITAT | -883.2 | -1,058.8 | -957.6 | -629.3 | 646.6 | -5,601.5 | -10,627.4 | -20,162.5 | -38,252.9 | -72,574.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,918.8 | -2,830.9 | -2,090.4 | -1,968.9 | -538.1 | -11,390.9 | -20,790.8 | -39,444.8 | -74,835.7 | -141,980.2 |
| WACC, % | 6.76 | 6.76 | 6.76 | 6.76 | 6.71 | 6.75 | 6.75 | 6.75 | 6.75 | 6.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -221,363.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -144,820 | |||||||||
| Terminal Value | -3,046,826 | |||||||||
| Present Terminal Value | -2,197,579 | |||||||||
| Enterprise Value | -2,418,943 | |||||||||
| Net Debt | 3,316 | |||||||||
| Equity Value | -2,422,259 | |||||||||
| Diluted Shares Outstanding, MM | 543 | |||||||||
| Equity Value Per Share | -4,457.82 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled financial data for SHANGHAI HENLIUS BIOTECH, INC. (2696HK).
- Comprehensive Data: Historical performance metrics and projected estimates (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth rates, EBITDA percentages, and WACC.
- Real-Time Calculations: Instantly observe how your inputs affect the valuation of SHANGHAI HENLIUS BIOTECH, INC. (2696HK).
- Professional Resource: Designed specifically for investors, CFOs, consultants, and financial analysts.
- User-Centric Layout: Organized for simplicity and ease of navigation, complete with step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Shanghai Henlius Biotech, Inc. (2696HK).
- WACC Calculator: Comes with a pre-constructed Weighted Average Cost of Capital sheet, allowing for adjustable inputs.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to suit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Shanghai Henlius Biotech, Inc. (2696HK).
- Interactive Dashboard and Charts: Visual representations that encapsulate essential valuation metrics for straightforward analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based SHANGHAI HENLIUS DCF Calculator for (2696HK).
- Input Your Assumptions: Modify the yellow-highlighted cells to set growth rates, WACC, margins, and other parameters.
- Instant Calculations: The model automatically refreshes to reflect the intrinsic value of Shanghai Henlius Biotech.
- Test Scenarios: Experiment with different assumptions to see how they impact valuation outcomes.
- Analyze and Decide: Leverage the findings to inform your investment choices or financial assessments.
Why Choose This Calculator for Shanghai Henlius Biotech, Inc. (2696HK)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for Henlius Biotech.
- Flexible Parameters: Modify the yellow-highlighted cells to explore various financial scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Henlius Biotech.
- Preloaded Information: Historical and projected data provides a solid foundation for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and business consultants focused on biotech.
Who Should Utilize This Product?
- Professional Investors: Construct comprehensive and accurate valuation models for portfolio assessments of Shanghai Henlius Biotech, Inc. (2696HK).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Shanghai Henlius Biotech, Inc. (2696HK).
- Students and Educators: Leverage real-world data to enhance practice and instruction in financial modeling.
- Biotech Enthusiasts: Gain insight into the valuation processes of biotech companies like Shanghai Henlius Biotech, Inc. (2696HK).
Contents of the Template
- Preloaded 2696HK Data: Historical and projected financial figures, including revenue, EBITDA, and capital expenditures.
- DCF and WACC Models: Advanced sheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial data for in-depth analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.